Kevin Gillinder

Kevin Gillinder is an Adjunct Senior Research Fellow at the Australian Centre for Blood Diseases, part of the Faculty of Medicine, Nursing and Health Sciences at Monash University, Melbourne. His research focuses on the molecular mechanisms of sequence-specific transcription factors, particularly their roles in DNA motif recognition, co-factor recruitment, and gene expression regulation in the context of blood disorders and cancers.

His research interests lie at the intersection of molecular biology, genomics, and haematology. He investigates how transcription factors such as KLF1 and KLF/SP family members regulate gene expression and how mutations can lead to neomorphic functions driving diseases like myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). His work combines biochemical, genomic, and functional approaches to dissect transcriptional dysregulation in cancer.

The recent publications highlight a strong focus on transcriptional regulation in hematopoietic systems, particularly in leukemia and erythropoiesis. Key themes include pioneer transcription factor activity, chromatin accessibility, protein-protein interactions in transcriptional complexes, and the pathological consequences of mutated transcription factors. His research spans from basic molecular mechanisms to translational applications in blood cancers.

• Seeding grant from the Ruby Red Foundation for the project: 'From Genomics to New Treatments for Myeloproliferative Neoplasms'

Kevin Gillinder has served as Primary Chief Investigator on a research project funded by the Ruby Red Foundation, demonstrating his ability to lead independent research initiatives. While no formal students are listed, his collaborative publications suggest mentorship and teamwork within larger research groups. He has held prior research roles at Mater Research Limited, University of Queensland, and Newcastle University (UK), indicating a well-established research trajectory.

He is affiliated with the Australian Centre for Blood Diseases, a leading research hub focused on blood cancers, coagulation disorders, and hematopoiesis. His work contributes to global efforts in understanding and treating hematological malignancies, aligning with UN Sustainable Development Goals related to good health and well-being.